ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Eton Pharmaceuticals, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$49.22−1.09 (-2.17%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 126.2
- Dividend yield
- –
Eton Pharmaceuticals, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Product Sales and Royalties [Member] | $76.66M | $38.51M | $26.14M | $11.25M | $2.83M | $39.00K | – | 95.9% | +99.1% |
| License [Member] | $3.29M | $500.00K | $5.50M | $10.00M | $19.00M | – | – | 4.1% | +557.2% |
| Product [Member] | – | – | – | – | $2.83M | $39.00K | $459.00K | – | – |
| Licensing Revenue [Member] | – | – | – | $10.00M | $19.00M | – | $500.00K | – | – |
By region
From the segment and revenue-disaggregation notes of Eton Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.